Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 7 | 2024 | 140 | 3.310 |
Why?
|
| Ataxia | 6 | 2024 | 51 | 3.220 |
Why?
|
| Tremor | 6 | 2024 | 60 | 3.200 |
Why?
|
| Postural Balance | 4 | 2025 | 62 | 2.250 |
Why?
|
| Huntington Disease | 2 | 2025 | 29 | 1.510 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2016 | 82 | 1.240 |
Why?
|
| Gait | 3 | 2020 | 195 | 1.110 |
Why?
|
| Psychomotor Performance | 2 | 2025 | 85 | 1.050 |
Why?
|
| Heterozygote | 3 | 2016 | 72 | 1.050 |
Why?
|
| Cerebral Cortex | 3 | 2025 | 77 | 1.010 |
Why?
|
| Parietal Lobe | 1 | 2025 | 11 | 0.930 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 66 | 0.890 |
Why?
|
| Male | 13 | 2025 | 6815 | 0.700 |
Why?
|
| Female | 12 | 2025 | 6974 | 0.640 |
Why?
|
| Aged | 8 | 2025 | 4000 | 0.640 |
Why?
|
| Walking Speed | 1 | 2020 | 13 | 0.630 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.620 |
Why?
|
| Nootropic Agents | 1 | 2020 | 7 | 0.620 |
Why?
|
| Middle Aged | 7 | 2025 | 4043 | 0.620 |
Why?
|
| Phenotype | 3 | 2016 | 157 | 0.610 |
Why?
|
| Databases, Factual | 1 | 2020 | 156 | 0.600 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 423 | 0.600 |
Why?
|
| Accidental Falls | 1 | 2020 | 39 | 0.600 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 67 | 0.580 |
Why?
|
| Humans | 12 | 2025 | 12240 | 0.550 |
Why?
|
| Movement Disorders | 1 | 2016 | 32 | 0.480 |
Why?
|
| Adult | 5 | 2025 | 3557 | 0.470 |
Why?
|
| Receptors, Estrogen | 5 | 1995 | 39 | 0.420 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.400 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 10 | 0.400 |
Why?
|
| Biomechanical Phenomena | 4 | 2022 | 297 | 0.350 |
Why?
|
| Walk Test | 2 | 2020 | 7 | 0.310 |
Why?
|
| Hippocampus | 4 | 1995 | 97 | 0.300 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 558 | 0.240 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 6 | 0.230 |
Why?
|
| Child | 2 | 2020 | 614 | 0.220 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 11 | 0.210 |
Why?
|
| Young Adult | 2 | 2020 | 863 | 0.210 |
Why?
|
| Adolescent | 2 | 2020 | 989 | 0.210 |
Why?
|
| Biomarkers | 1 | 2024 | 294 | 0.180 |
Why?
|
| Shoes | 1 | 2022 | 13 | 0.180 |
Why?
|
| Walking | 1 | 2022 | 108 | 0.170 |
Why?
|
| Animals | 7 | 2016 | 2092 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 2152 | 0.160 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 3 | 0.160 |
Why?
|
| Foot | 1 | 2020 | 17 | 0.160 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 10 | 0.160 |
Why?
|
| Reference Values | 1 | 2020 | 103 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 214 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2020 | 256 | 0.150 |
Why?
|
| Child, Preschool | 1 | 2020 | 320 | 0.150 |
Why?
|
| Motor Activity | 1 | 2020 | 175 | 0.140 |
Why?
|
| Time Factors | 1 | 2020 | 695 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 16 | 0.120 |
Why?
|
| Brain Tissue Transplantation | 2 | 1993 | 9 | 0.120 |
Why?
|
| Posture | 1 | 2016 | 20 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2016 | 66 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2016 | 105 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 9 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 27 | 0.120 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2015 | 27 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 53 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 105 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 35 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 290 | 0.110 |
Why?
|
| Animals, Newborn | 3 | 1993 | 29 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2020 | 1478 | 0.110 |
Why?
|
| Cognition | 1 | 2020 | 641 | 0.110 |
Why?
|
| Sexual Behavior, Animal | 1 | 1994 | 1 | 0.110 |
Why?
|
| Pituitary-Adrenal System | 1 | 1994 | 2 | 0.110 |
Why?
|
| Retrospective Studies | 1 | 2020 | 1467 | 0.110 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1994 | 9 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 17 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 1995 | 157 | 0.110 |
Why?
|
| Arousal | 1 | 1994 | 27 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 182 | 0.110 |
Why?
|
| Rats | 6 | 1995 | 407 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 464 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2016 | 827 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 27 | 0.100 |
Why?
|
| Movement | 1 | 2013 | 58 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Neurons | 2 | 1995 | 164 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2016 | 314 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 546 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 225 | 0.050 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1993 | 12 | 0.050 |
Why?
|
| Estradiol | 2 | 1993 | 26 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 10 | 0.040 |
Why?
|
| Pregnancy | 2 | 1993 | 193 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 324 | 0.040 |
Why?
|
| Aging | 2 | 1993 | 680 | 0.030 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 1995 | 2 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1995 | 7 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 7 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 13 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 16 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 26 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1994 | 3 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 2 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 97 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1994 | 59 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 15 | 0.030 |
Why?
|
| Cytosol | 2 | 1992 | 32 | 0.030 |
Why?
|
| Age Factors | 1 | 1995 | 350 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 125 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 2 | 0.030 |
Why?
|
| Preoptic Area | 1 | 1993 | 2 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1993 | 32 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 288 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1990 | 2 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 3 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 42 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 110 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 229 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 1 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 9 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1995 | 15 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 275 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 93 | 0.010 |
Why?
|